Please login to the form below
Rixathon/Riximyo
This page shows the latest Rixathon/Riximyo news and features for those working in and with pharma, biotech and healthcare.
Sandoz joins Europe's MabThera biosimilar push
Sandoz will sell its biosimilar under the Rixathon/Riximyo brand names, and the firm's biopharma head, Carol Lynch, said the approval is "a big win for patients in Europe with ... There is no word on pricing for Rixathon just yet, but biosimilars
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Senior Writer, Healthcare Advertising, London
-
Excellent package
-
Systematic Review Lead- London
-
Negotiable
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
-
Account Manager
-
Negotiable
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Medical Writers Required - Hertfordshire
-
Competitive
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Sudler London - Senior Medical Writer
-
Competitive
-
Sudler London - Account Director
-
Competitive
-
Associate Scientific Director
-
Salary TBC
Subscribe to our email news alerts
- Tox trouble stalls Sosei/Allergan Alzheimer’s drug
- London cancer hub launched by Cancer Research UK
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Making a Difference - The Future of Pharma
- AZ prepares to file COPD triple, taking on rival GSK
- Controversy grows around GP at Hand service after minister’s endorsement
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
